Table 1.

Colorado Scoring Criteria for EGFR FISH. The table includes the number of eligible patients from the SQUIRE trial, divided by scoring category and treatment arm.

Score	Observation	N# of patients (%)			EGFR signal features	FISH result Patients (%)
		Arm A	Arm B	Overall
1	Disomy	11 (3.9%)	13 (4.7%)	24 (4.3%)	< 40% of cells displaying ≥ 4 copies of the EGFR signal AND EGFR/CEP7 ratio < 2 AND absence of gene clusters AND < 10% of cells displaying ≥ 15 copies of EGFR	Negative 349 (62.7%)
2	Low trisomy	61 (21.6%)	56 (20.4%)	117 (21.0%)
3	High trisomy	10 (3.5%)	13 (4.7%)	23 (4.1%)
4	Low polysomy	89 (31.6%)	96 (34.9%)	185 (33.2%)
5	High polysomy	89 (31.6%)	78 (28.4%)	167 (30.0%)	≥ 40% of cells displaying ≥ 4 copies of the EGFR signal*	Positive 208 (37.3%)
6	Gene amplification	22 (7.8%)	19 (6.9%)	41 (7.4%)	EGFR/CEP7 ratio ≥ 2 OR presence of gene clusters (≥ 4 spots) OR ≥ 10% of cells displaying ≥ 15 copies of EGFR*
	TOTAL	282 (50.6%)	275 (49.4%)	557 (100%)

Arm A: cisplatin-gemcitabine-necitumumab; Arm B: cisplatin-gemcitabine.

^*If a sample met the critieria for both high polysomy and gene amplification, the sample was categorized as score=6.